The real-life data of hospitalized patients with heart failure: on behalf of the Journey HF-TR study investigators

Basit Öğe Kaydı
dc.contributor.authorSinan, Ümit Yaşar
dc.contributor.authorEkmekçi, Ahmet
dc.contributor.authorÖzbay, Benay
dc.contributor.authorAkyıldız, Filiz Akçay
dc.contributor.authorBekar, Lütfü
dc.contributor.authorKoza, Yavuzer
dc.contributor.authorKocabaş, Umut
dc.date.accessioned2020-12-01T12:37:06Z
dc.date.available2020-12-01T12:37:06Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Acute heart failure (AHF) is a life-threatening clinical syndrome characterized by rapid onset of heart failure (HF) symptoms and signs and requires urgent therapy. the aim of the present study was to evaluate the overall clinical characteristics, management, and in-hospital outcomes of hospitalized patients with AHF in a large sample of Turkish population. Methods: the Journey HF-TR study is a cross-sectional, multicenter, non-invasive and observational trial. Patients who were hospitalized with a diagnosis of AHF in the intensive care unit (ICU)/coronary care unit and cardiology wards between September 2015 and September 2016 were included in our study. Results: A total of 1606 (male: 57.2%, mean age: 67.8±13 years) patients who were diagnosed with AHF were enrolled in the study. Seventeen percent of the patients were admitted to the hospital with a diagnosis of new onset AHF. Hypertension (67%) and coronary artery disease (CAD) (59.6%) were the most frequent underlying diseases. Acute coronary syndrome accompanying HF (14.7%), infection (29.3%), arrhythmia (25.1%), renal dysfunction (23%), and non-compliance with medication (23.8%) were the precipitating factors. the median length of stay in the ICU was 3 days (interquartile range, IQR 1–72) and 7 days (IQR 1–72) for in-hospital journey. the guideline recommended medications were less likely used in our patient population (<73%) before admission and were similar to European and US registers at discharge. the in-hospital mortality rate was 7.6%. Hypertension and CAD were the most frequent underlying diseases in our population similar to other European surveys. Although our study population was younger than other registers, in-hospital mortality was high. Conclusion: Analyses of such real-world data will help to prepare a national database and distinctive diagnosis and treatment algorithms and to provide observing compliance with the current European Society of Cardiology guidelines for more effective management of HF. (Anatol J Cardiol 2019; 21: 25-30)en_US
dc.identifier.doi10.14744/AnatolJCardiol.2018.50880
dc.identifier.endpage30en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue1en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2018.50880
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TXpZNE5qa3lNZz09
dc.identifier.urihttps://hdl.handle.net/11454/67097
dc.identifier.volume21en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofThe Anatolian Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject0-Belirleneceken_US
dc.titleThe real-life data of hospitalized patients with heart failure: on behalf of the Journey HF-TR study investigatorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu